▲Source of the article: Eshare Medical Device Collection▲Please indicate the above source at the beginning of the article when reprinting.Recently, Medtronic inAmerican Diabetes Association (ADA)A series of new data was presented at the 84th Scientific Meeting to demonstrate the advantages of the MiniMed™ 780G system.The MiniMed™ 780G system reduces the occurrence of morning hyperglycemia and improves nighttime sleep with its advanced algorithm that automatically corrects every 5 minutes.。
Image source: Medtronic official websiteMerge and Acquire, Become the All-Round LeaderMedtronic Diabetes Business is an important division of Medtronic, a global medical device giant, focusing on providing comprehensive solutions for people with diabetes.Its predecessor, Minimed Technologies (or Medtronic Minimed), was founded by Alfred E. Mann.Founded in 1983, focusing on providing more convenient and precise insulin delivery systems for diabetic patients.MiniMed™502 is an early wearable insulin pump launched by MiniMed Technologies. Patients with diabetes use a small device to better manage insulin delivery, thereby achieving better control of their blood glucose levels.Over time, Minimed Technologies has continuously expanded its product line with the launch of products such as the MiniMed™ 506 and MiniMed™ 508, while introducing more innovative technologies for diabetes management.Arrived2001Medtronic acquires MiniMed, Inc. and Medical Research Group (MRG) in a mergerMedtronic MiniMed, Inc., as the diabetes business unit of Medtronic。Through technology integration, Medtronic strengthens its innovation and product development capabilities in the field of diabetes management. Medtronic launches an insulin pump with a bolus guide function, laying the foundation for the future development of the artificial pancreas, which dynamically monitors blood glucose and administers medication differentially based on individual characteristics.After more than 20 years of development, Medtronic is now the leader in the insulin infusion pump market and alsoA full-line company producing insulin infusion pumps and continuous glucose monitoring (CGM) systems。Artificial Pancreas, Helping Improve LivesInsulin Infusion Pump TherapyRefers to the adoption ofArtificial Intelligence-Controlled Insulin Delivery Device(Insulin Pump), throughContinuous Subcutaneous Insulin InfusionTreatment methods.Insulin pump therapy can simulate the physiological secretion pattern of insulin, which means a small amount of basal insulin is secreted continuously, and a large amount of bolus insulin is secreted during meals, thereby helping patients achieve better blood glucose control.Continuous Glucose Monitoring (CGM) refers to the process ofMicroelectrodes implanted in subcutaneous tissue record electrical signals generated by glucose oxidation reactions in interstitial fluid., indirectly reflecting the new type of blood glucose measurementMinimally Invasive Blood Glucose Monitoring Technology.By storing blood glucose values to form a continuous blood glucose profile, patients can conveniently and accurately record their daily lives based on blood glucose fluctuations.Combining both and connecting them through mobile or computer software to form a closed loop, where the software assists in achieving automatic blood glucose regulation akin to the function of human organs, is known as the Hybrid Closed-Loop Insulin Delivery System (AID), also referred to as the "Artificial Pancreas."And the best of them is Medtronic's flagship product.MiniMed™ 780G。Source: Medtronic official websiteCutting-edge Products, Reaching New Revenue HeightsMiniMed™ 780GThe system is the latest HCL insulin pump system,June 2020Approved by the EU CE for Type 1 diabetic patients aged 7 to 80.April 2023Medtronic MiniMed™ 780G System Receives FDA Approval.The MiniMed™ 780G system includes the 780G pump, the third and fourth generations of Medtronic's Guardian™ Sensor 3, 4 Continuous Glucose Monitoring (CGM), and an automated insulin adjustment algorithm.The SmartGuard™ technology, based on the IPD+IFB algorithm and featured in the 780G system, ensuresEvery 5 minutesAutomatically fine-tune dosage in response to high or low blood glucose trends, helping patients prevent hyperglycemia or hypoglycemia.The MiniMed™ 780G system has the lowest blood glucose target setting among all automatic insulin pumps on the market.(As low as 5.6mmol/L), and more closely reflect the average blood glucose of non-diabetic patients. With this setting, the pump will "treat to target," automatically providing basal insulin adjustments and automatic corrections to reach the set target.In terms of the current closed-loop insulin pump technology used for Type 1 diabetes, the MiniMed 780G can be considered the most advanced.Excellent products have also drivenMedtronic Diabetes' Performance Growth.Medtronic's 2024 financial report showsMedtronic Diabetes Performance from Fiscal Year 2023$2.262 billion, increasing to the fiscal year 2024$24.88 billion, with a growth rate reaching double digits, far surpassing other departments.Medtronic itself revealed that the MiniMed™ 780G system was one of the main drivers behind its sales growth.
Source: Eshare Medical Device Hub Production
Diabetes, as a currently incurable chronic disease, requires maintaining good blood glucose control to reduce acute and chronic complications, enabling the majority of diabetic patients to achieve nearly the same quality of life and life expectancy as ordinary people.New technologies such as novel insulin, insulin pumps, and continuous glucose monitoring (CGM) have continuously emerged, indeed helping diabetes patients extend their healthy life expectancy.It is hoped that in the near future, more patients will be able to use advanced diabetes technology as soon as possible to assist in managing diabetes and reduce or delay the suffering caused by complications.Note:The above content is for reference only and does not constitute investment advice.The interpretation of official policies in this article only represents the views of this platform, and the content is subject to official documents. If any platform reprints this article, it must take responsibility for the article itself and is not responsible for the impact of secondary dissemination caused by the reprint.
China Medical Device Blue Book (2024 Edition)
If you like it, click "Watch" before you go.
